BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

How Might Biomolecular Condensates Revolutionize Drug Discovery?

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates ar...

August 18, 2022 | Opinion

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announ...

August 17, 2022 | News

Lumicera Health Services Now Offering The First Landmark Drug From CivicaScript™

Abiraterone, which is used with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body, is the first of six to...

August 12, 2022 | News

Taiwan FDA accepts New Drug Application for Xerava for treatment of cIAI

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative ph...

August 11, 2022 | News

Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply

U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the JYNNEOS vaccine to allow healthcare providers to use the vaccine by i...

August 10, 2022 | News

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple cytokine-induced signaling pathways in vitro and in vivo. LNK01004 is tissue-...

August 04, 2022 | News

Lynk Pharmaceuticals Announces First Participants in Phase I Trial of LNK01004

This study is to evaluate the safety, tolerability, and pharmacokinetics of the LNK01004 ointment in healthy adults and patients with mild to moderate plaq...

July 29, 2022 | News

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously d...

July 27, 2022 | News

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

In around a year since the collaboration was established, the two parties have screened out a number of fully human therapeutic antibody clones with excell...

July 25, 2022 | News

China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON

NR082 (rAAV2-ND4), a recombinant adeno-associated viral vector, serotype 2, containing human ND4 codon-optimized gene under the control of the cy...

July 18, 2022 | News

Triastek & Lilly to explore the application of 3D printing technology in oral delivery of drugs

According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct ...

July 14, 2022 | News

Sobi to license loncastuximab tesirine from ADC Therapeutics

Sobi® announced an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesirine for use in haematology and ...

July 11, 2022 | News

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in les...

July 07, 2022 | News

EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement

In this alliance, MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS disease by utilizing the drug R&D know-how and ...

July 06, 2022 | News

Stay Connected